The Anglo-Scandinavian Cardiac Outcomes Trial: blood pressure-lowering limb: effects in patients with type II diabetes
The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: To compare the effects of two antihypertensive treatment strategies for the prevention of coronary heart disease and other cardiovascular events in the large subpopulation (n=5137) with diabetes mellitus in the blood pressure-lowering arm of the Anglo-Scandinavian Cardiac Outcomes Trial. METHODS: Patients had either untreated hypertension or treated hypertension. For those with type II diabetes mellitus, inclusion criteria required at least two additional risk factors. Patients were randomized to amlodipine with addition of perindopril as required (amlodipine-based) or atenolol with addition of thiazide as required (atenolol-based). Therapy was titrated to achieve a target blood pressure of less than 130/80 mmHg. RESULTS: The trial was terminated early due to significant benefits on mortality and stroke associated with the amlodipine-based regimen. In patients with diabetes mellitus, the amlodipine-based treatment reduced the incidence of the composite endpoint--total cardiovascular events and procedures--compared with the atenolol-based regimen (hazard ratio 0.86, confidence interval 0.76-0.98, P=0.026). Fatal and nonfatal strokes were reduced by 25% (P=0.017), peripheral arterial disease by 48% (P=0.004) and noncoronary revascularization procedures by 57% (P<0.001). For the other endpoints included in the composite, the endpoint differences were less clear including coronary heart disease deaths and nonfatal myocardial infarctions (the primary endpoint), which were reduced nonsignificantly by 8% (hazard ratio 0.92, confidence interval 0.74-1.15). CONCLUSION: In the large diabetic subgroup in the blood pressure-lowering arm of the Anglo-Scandinavian Cardiac Outcomes Trial, the benefits of amlodipine-based treatment, compared with atenolol-based treatment, on the incidence of total cardiovascular events and procedures was significant (14% reduction) and similar to that observed in the total trial population (16% reduction).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“All available BP-lowering drugs can be used, but evidence strongly supports using a renin-angiotensin system (RAS) inhibitor (ACE-I, ARB), particularly in patients with evidence of end-organ damage (albuminuria and left ventricular [LV] hypertrophy).”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [215]
Citations
Cites
Stamler, J., Vaccaro, O., Neaton, J. D., Wentworth, D., & The Multiple Risk Factor Intervention Trial Research Group (1993) · Diabetes Care · doi:10.2337/diacare.16.2.434 · Cited by 4,063
Sever, P. S., Dahlöf, B., Poulter, N. R., Wedel, H., Beevers, G., Caulfield, M., Collins, R., Kjeldsen, S. E., Kristinsson, A., McInnes, G. T., et al. (2003) · The Lancet · doi:10.1016/s0140-6736(03)12948-0 · Cited by 3,782
Self-citationSarnak, M. J., Levey, A. S., Schoolwerth, A. C., Coresh, J., Culleton, B., Hamm, L. L., McCullough, P. A., Kasiske, B. L., Kelepouris, E., Klag, M. J., et al. (2003) · Circulation · doi:10.1161/01.cir.0000095676.90936.80 · Cited by 3,768
Dahlöf, B., Sever, P. S., Poulter, N. R., Wedel, H., Beevers, D. G., Caulfield, M., Collins, R., Kjeldsen, S. E., Kristinsson, A., McInnes, G. T., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67185-1 · Cited by 2,909
Self-citationMorbidity and mortality in diabetics in the Framingham population. Sixteen year follow-up study
Garcia, M. J., McNamara, P. M., Gordon, T., & Kannell, W. B. (1974) · Diabetes · doi:10.2337/diab.23.2.105 · Cited by 1,608
Lindholm, L. H., Ibsen, H., Dahlöf, B., Devereux, R. B., Beevers, G., de Faire, U., Fyhrquist, F., Julius, S., Kjeldsen, S. E., Kristiansson, K., et al. (2002) · The Lancet · doi:10.1016/s0140-6736(02)08090-x · Cited by 1,560
Self-citationEstacio, R. O., Jeffers, B. W., Hiatt, W. R., Biggerstaff, S. L., Gifford, N., & Schrier, R. W. (1998) · New England Journal of Medicine · doi:10.1056/nejm199803053381003 · Cited by 1,166
Effects of Calcium-Channel Blockade in Older Patients with Diabetes and Systolic Hypertension
Tuomilehto, J., Rastenyte, D., Birkenhäger, W. H., Thijs, L., Antikainen, R., Bulpitt, C. J., Fletcher, A. E., Forette, F., Goldhaber, A., Palatini, P., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199903043400902 · Cited by 940
Research works printed but not linked: 1
- Lievre, 2000, INDANA Steering Committee. Efficacy of diuretics and β-blockers in diabetic hypertensive patients: results from a meta-analysis, Diabetes Care, 23, B65
Cited by
Cosentino, F., Grant, P. J., Aboyans, V., Bailey, C. J., Ceriello, A., Delgado, V., Federici, M., Filippatos, G., Grobbee, D. E., Hansen, T. B., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehz486 · Cited by 4,763
Mechanisms of Diabetic Complications
Forbes, J. M., & Cooper, M. E. (2013) · Physiological Reviews · doi:10.1152/physrev.00045.2011 · Cited by 2,890
“However, increasingly these agents are being used as part of combination regimens with blockers of the RAAS and have been shown in that setting to be useful in terms of blood pressure lowering and reduced adverse cardiovascular outcomes, as seen in the diabetic cohorts from the ACCOMPLISH (19) and ASCOT trials (444).”
BackgroundMeschia, J. F., Bushnell, C., Boden-Albala, B., Braun, L. T., Bravata, D. M., Chaturvedi, S., Creager, M. A., Eckel, R. H., Elkind, M. S. V., Fornage, M., et al. (2014) · Stroke · doi:10.1161/str.0000000000000046 · Cited by 2,650
(2013) · European Heart Journal · doi:10.1093/eurheartj/eht108 · Cited by 1,955
Self-citation2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes.
Marx, N., Federici, M., Schütt, K., Müller-Wieland, D., Ajjan, R. A., Antunes, M. J., Christodorescu, R. M., Crawford, C., Di Angelantonio, E., Eliasson, B., et al. (2023) · European Heart Journal · doi:10.1093/eurheartj/ehad192 · Cited by 1,642
Metadata
- Authors
- Östergren, J., Poulter, N. R., Sever, P. S., Dahlöf, B., Wedel, H., Beevers, G., Caulfield, M., Collins, R., Kjeldsen, S. E., Kristinsson, A., McInnes, G. T., Mehlsen, J., Nieminen, M., & O'Brien, E.
- Affiliations
- Karolinska University Hospital (SE)
- Imperial College London (GB)
- Sahlgrenska University Hospital (SE)
- Nordic School of Public Health (SE)
- Birmingham City Hospital (GB)
- Queen Mary University of London (GB)
- University of Oxford (GB)
- Oslo University Hospital (NO)
- National University Hospital of Iceland (IS)
- University of Glasgow (GB)
- Frederiksberg Hospital (DK)
- Helsinki University Hospital (FI)
- Beaumont Hospital (IE)
- Corresponding author
- Östergren, Jan
- ORCID
- Venue
- Journal of Hypertension
- Published
- 2008-11
- Volume
- 26
- Issue
- 11
- Pages
- 2103-2111
- ISSN
- 0263-6352 (ISSN-L)
- OpenAlex
- W2106630546
- Cited by
- 116
- References
- 31
- Citations by year
- 2026: 2 · 2025: 2 · 2024: 1 · 2023: 4 · 2022: 5 · 2021: 5 · 2020: 2 · 2019: 3 · 2018: 7 · 2017: 6 · 2016: 3 · 2015: 4 · 2014: 18 · 2013: 11 · 2012: 7
- FWCI
- 8.48
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of Hypertension (publishedVersion)
- PubMed (publishedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (submittedVersion)
- Funders
- Pfizer
- Heart and Stroke Foundation of Canada
- Servier
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Blood Pressure and Hypertension Studies
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart rate and cardiovascular health
- Keywords
- type 2 diabetes, hypertension, amlodipine, atenolol, perindopril, thiazide diuretics, combination antihypertensive therapy, cardiovascular events, stroke, peripheral arterial disease, coronary artery disease
- MeSH terms
- Adult, Aged, Antihypertensive Agents, Atenolol, Blood Pressure, Cardiovascular Diseases, Diabetes Mellitus, Type 2, Drug Therapy, Combination, Female, United Kingdom, Humans, Hypertension, Male, Middle Aged, Scandinavian and Nordic Countries, Peripheral Vascular Diseases, Amlodipine, Stroke, Perindopril, Thiazides
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The Anglo-Scandinavian Cardiac Outcomes Trial: blood pressure-lowering limb: effects in patients with type II diabetes. https://app.cochat.ai/papers/10.1097/hjh.0b013e328310e0d9
- The paper
- Östergren, J., Poulter, N. R., Sever, P. S., Dahlöf, B., Wedel, H., Beevers, G., Caulfield, M., Collins, R., Kjeldsen, S. E., Kristinsson, A., McInnes, G. T., Mehlsen, J., Nieminen, M., & O'Brien, E. (2008). The Anglo-Scandinavian Cardiac Outcomes Trial: blood pressure-lowering limb: effects in patients with type II diabetes. Journal of Hypertension. https://doi.org/10.1097/hjh.0b013e328310e0d9
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.